Senolytics Ranked by Evidence: FOXO4-DRI, Dasatinib + Quercetin, Fisetin and More
An evidence-anchored ranking of senolytics — Dasatinib+Quercetin, fisetin, navitoclax, FOXO4-DRI — showing what human and mouse data actually support, and where the field has failed.
By weight of evidence, Dasatinib+Quercetin leads because it has small human pilot data plus mouse lifespan results; fisetin follows on mouse data and ongoing human trials with no efficacy results yet; FOXO4-DRI rests on a single mouse paper. No senolytic has a positive human randomized trial.
Senolytics are drugs and peptides that kill senescent cells — cells that have stopped dividing but refuse to die and secrete a pro-inflammatory mix that damages surrounding tissue. The category is small, the marketing is loud, and the actual evidence is uneven. Ranking these compounds honestly means separating a molecule with human pilot data from one resting on a single mouse paper, and admitting where the field has already failed a controlled trial. Everything below describes laboratory and clinical-literature findings, not use in people.
What is a senolytic, mechanistically?
Senescent cells survive by upregulating pro-survival networks — the senescent-cell anti-apoptotic pathways, or SCAPs — that keep them from triggering their own apoptosis. Zhu and colleagues mapped these networks in 2015 and used them to nominate the first senolytics, reasoning that transiently disabling a SCAP node would push senescent cells (but not healthy quiescent cells) into death.1 That paper introduced the Dasatinib+Quercetin (D+Q) combination that still anchors the field. The design logic matters: senolytics are given intermittently — a “hit-and-run” schedule — because senescent cells accumulate slowly and the goal is periodic clearance, not chronic pathway suppression.
Dasatinib is an FDA-approved BCR-ABL/Src tyrosine-kinase inhibitor used in leukemia; quercetin is a plant flavonoid. Neither was designed as a longevity agent. The senolytic hypothesis simply repurposes their combined ability to disrupt distinct SCAP nodes across different senescent-cell types. That repurposing runs through the entire category — several leading senolytics are oncology cast-offs, which shapes both their potency and their toxicity.
How the compounds actually rank
A defensible ranking follows the depth of evidence, not the strength of the biology story. The tier that matters most is whether a compound has been tested in humans, and with what result.
| Compound | Best evidence | Human data | Key limitation |
|---|---|---|---|
| Dasatinib + Quercetin | Mouse lifespan/function; two human pilots | Open-label pilots (n=14, n=9) | No placebo; corrigendum on kidney report |
| Fisetin | One mouse lifespan paper; human RCTs ongoing | Trials running, no efficacy results | Lifespan claim not replicated by NIA ITP |
| Navitoclax (ABT-263) | Strong animal senolysis | None as a longevity agent | Dose-limiting thrombocytopenia; can worsen PH |
| FOXO4-DRI | Single 2017 mouse paper | None | Single-lab, animal-only |
| Quercetin alone | Weak senolytic activity | None meaningful | Much weaker than in combination |
| UBX0101 (UBX-class) | Preclinical joint senolysis | Failed Phase 2 | Did not beat placebo; program stopped |
All entries describe in-vitro, animal, or early-phase clinical literature only. Nothing here is a dosing recommendation or a claim of human efficacy.
1. Dasatinib + Quercetin — the most human-tested, still on thin ice
D+Q sits at the top because it is the only senolytic with both mouse lifespan data and human data. In old mice, intermittent D+Q improved physical function and increased post-treatment survival, and even transplanting a small number of senescent cells was enough to cause physical dysfunction that senolytics partly reversed.9 On the human side, Justice 2019 gave intermittent D+Q to 14 patients with idiopathic pulmonary fibrosis over three weeks and reported improved six-minute walk distance, gait speed and chair-stand performance — but no change in pulmonary function or measured SASP markers.2 Hickson 2019 then supplied the first direct human evidence that D+Q reduces senescent-cell burden: in nine patients with diabetic kidney disease, three days of oral dosing lowered p16/p21-positive and SA-β-gal-positive cells in adipose and skin about eleven days later.3
23 the combined number of patients across both published D+Q human pilots — and neither had a placebo arm.
2. Fisetin — mouse claim contested, human results pending
Fisetin is a flavonoid senotherapeutic that reached prominence when Yousefzadeh 2018 reported reduced senescence markers and extended median and maximum lifespan in aged mice.4 It has since moved into actual human trials: a COVID-19 senolytic study in skilled-nursing-facility residents,6 and a current randomized, placebo-controlled Phase 2 protocol (TROFFi) in breast-cancer survivors.7 That is genuine controlled-trial activity — but no efficacy outcomes have been reported, so “in human trials” is true while “proven in humans” is not.
Being in a randomized trial and having a positive result from one are not the same thing — and for every senolytic on this list, the second has not happened.
3. Navitoclax (ABT-263) — potent and genuinely toxic
Navitoclax is a Bcl-2/Bcl-xL inhibitor from oncology and a strong senolytic in animal models. It is not a benign longevity candidate: it carries dose-limiting thrombocytopenia, and its potency in animals does not imply safety as a repeated intervention. It also features in the field’s clearest cautionary result, below.
4. FOXO4-DRI — one mouse paper, one lab
FOXO4-DRI is a peptide that interferes with the FOXO4–p53 interaction, releasing p53 to trigger apoptosis selectively in senescent cells. The foundational report, Baar 2017, showed that the peptide killed senescent cells and improved fitness, fur density and renal function in aged and progeroid mice.8 That is a striking result, but it is essentially the whole evidence base: mouse-only, with no independent human replication and no human data at all. For a compound frequently discussed as a longevity tool, that single-lineage footing is the central fact. We cover the underlying peptide in more depth in our FOXO4-DRI primer.
5. Quercetin alone / 6. UBX-class
Quercetin on its own is a weak senolytic; its activity is far smaller than in the dasatinib pairing, which is why the combination — not the flavonoid — carries the human data. The UBX class occupies a different tier entirely: it is the one senolytic lineage tested in a completed placebo-controlled human trial, and it failed (see below).
An honest read of the evidence
The strongest honest statement about this category is short: no senolytic has a positive human randomized controlled trial with clinical endpoints. Everything ranked above rests on animal data, uncontrolled human pilots, or trials that are still running.
The human D+Q data are tiny and uncontrolled — roughly 23 patients total across two open-label pilots with no placebo, and the diabetic-kidney report required a published corrigendum, which is worth stating plainly when it is the flagship human senolysis dataset.23 Fisetin’s headline lifespan claim is contested at the source: the NIA Interventions Testing Program — a rigorous, multi-site protocol built specifically to filter out non-reproducible longevity claims in genetically heterogeneous mice — found no significant lifespan extension from fisetin, directly undercutting the 2018 report.5 FOXO4-DRI’s animal-only, single-lab footing has already been noted; the replication gap is the story, not a footnote.
Senolysis is also not uniformly good. Born 2023 showed that clearing senescent cells — including with navitoclax — worsened pulmonary hypertension in models, meaning the intuitive “clear senescent cells = benefit” framing is context-dependent and can cause harm.10 And the field’s own lead clinical asset failed: Unity Biotechnology’s UBX0101 did not beat placebo on pain in a Phase 2 knee-osteoarthritis trial in 2020, and the program was discontinued.12 A recent authoritative review from the Mayo senescence group frames these translational tiers in the metabolic and longevity context and is the right place to calibrate expectations.11 For adjacent longevity mechanisms handled with the same evidentiary caution, see our notes on spermidine and autophagy, NMN, and IGF-1/mTOR signalling.
All materials supplied by Condor Research are Research Use Only (RUO). The findings summarized above are drawn from in-vitro, animal, and early-phase clinical literature; nothing here is a dosing protocol, clinical guidance, or a safety assessment for any organism. No senolytic described is offered or framed for human or veterinary use.
Condor Research · Scientific desk
Atrio Sciences s.r.o., IČO 57 669 651, Nitra (SK) · info@condorresearch.com
- Senolytics selectively kill senescent cells by blocking the pro-survival (SCAP) pathways those cells depend on; the concept and the Dasatinib+Quercetin combination trace to Zhu 2015.
- Dasatinib+Quercetin is the most human-tested senolytic, but the human data are two small open-label pilots (n=14 and n=9) with no placebo — one report later required a published corrigendum.
- Fisetin extended mouse lifespan in one 2018 report, but the rigorous NIA Interventions Testing Program found no lifespan benefit in 2024; human trials are ongoing with no efficacy results reported.
- FOXO4-DRI is a FOXO4–p53-interfering peptide supported by essentially one 2017 mouse paper — mouse-only, single-lab, zero human data.
- Navitoclax (ABT-263) is a potent senolytic in animals but is oncology-derived and carries dose-limiting thrombocytopenia.
- Senolysis is not uniformly beneficial: one 2023 study showed clearing senescent cells worsened pulmonary hypertension in models.
- The field's lead clinical asset, Unity's UBX0101, failed its Phase 2 knee-osteoarthritis trial in 2020 and the program was stopped — no senolytic has a positive human RCT with clinical endpoints.
Which senolytic has the most human evidence?
Dasatinib+Quercetin. It is the only combination with both mouse lifespan/function data and human data. That human data, however, is limited to two small open-label pilots — Justice 2019 in idiopathic pulmonary fibrosis (n=14) and Hickson 2019 in diabetic kidney disease (n=9) — neither of which had a placebo arm.
Has any senolytic passed a human randomized controlled trial?
No senolytic has a positive human RCT with clinical endpoints. The current human senolysis literature is either early-phase uncontrolled pilots (D+Q) or ongoing controlled trials with no reported results (fisetin). The one completed placebo-controlled Phase 2, Unity's UBX0101, failed to separate from placebo.
Is fisetin proven to extend lifespan?
Not reliably. One 2018 mouse study reported lifespan extension, but the NIA Interventions Testing Program — designed to catch exactly this kind of non-reproducible claim — found no significant lifespan effect in heterogeneous mice. Human fisetin efficacy remains unreported despite active trials.
Why is FOXO4-DRI ranked below D+Q and fisetin?
Because its evidence base is essentially a single 2017 mouse paper. The mechanism (disrupting the FOXO4–p53 interaction to release p53) is elegant and the animal results were notable, but there is no independent replication and no human data at all. A single-lab, animal-only footing places it below compounds that at least have human safety pilots or ongoing controlled trials.
Is clearing senescent cells always beneficial?
No. Born 2023 demonstrated that eliminating senescent cells — including with the senolytic navitoclax — worsened pulmonary hypertension in models. Senescent cells play context-dependent roles, and indiscriminate clearance can be harmful in some tissues and conditions.
Is navitoclax a good longevity candidate?
Navitoclax (ABT-263) is a potent senolytic in animals, but it is an oncology-derived Bcl-2/Bcl-xL inhibitor with dose-limiting thrombocytopenia. Strong preclinical potency has not translated into a safe or validated longevity intervention, and it is implicated in the pulmonary-hypertension caveat above.